-
Tytuł:
-
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
-
Autorzy:
-
Iftikhar R; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan. Electronic address: .
Chaudhry QUN; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Anwer F; Department of Hematology, Medical Oncology, Tausig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, United States.
Neupane K; Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara 33700, Nepal.
Rafae A; Department of Internal Medicine, McLaren Flint Michigan State University, United States.
Mahmood SK; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Ghafoor T; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Shahbaz N; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khan MA; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khattak TA; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Shamshad GU; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Rehman J; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Farhan M; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Khan M; Department of Hematology and Stem Cell Transplant, Armed Forces Bone Marrow Transplant Center/National Institute of Blood and Marrow Transplant, Rawalpindi 46000, Pakistan.
Ansar I; Shifa College of Medicine, Islamabad 44000, Pakistan.
Ashraf R; King Edward Medical University, Lahore 54000, Pakistan.
Marsh J; Department of Hematological Medicine, King's College Hospital, Denmark Hill, London SE59RS, UK.
Satti TM; Shifa International Hospital, Islamabad 44000, Pakistan.
Ahmed P; Department of Hematology Oncology and Stem Cell Transplant, Quaid-e-Azam International Hospital, Islamabad 44000, Pakistan.
-
Źródło:
-
Blood reviews [Blood Rev] 2021 May; Vol. 47, pp. 100772. Date of Electronic Publication: 2020 Oct 31.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2001- : London : Elsevier
Original Publication: [Edinburgh ; New York] : Churchill Livingstone, [c1987-
-
MeSH Terms:
-
Hematopoietic Stem Cell Transplantation*
Immunosuppression Therapy*
Transplantation Conditioning*
Anemia, Aplastic/*therapy
Graft Rejection/*prevention & control
Graft vs Host Disease/*prevention & control
Age Factors ; Allografts ; Antilymphocyte Serum/therapeutic use ; Cyclosporine/therapeutic use ; Humans ; Methotrexate/therapeutic use ; Risk Factors ; Unrelated Donors ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use
-
Contributed Indexing:
-
Keywords: Aplastic anemia; Graft vs host disease; Peripheral blood stem cells; Stem cell transplantation
-
Substance Nomenclature:
-
0 (Antilymphocyte Serum)
83HN0GTJ6D (Cyclosporine)
FA2DM6879K (Vidarabine)
P2K93U8740 (fludarabine)
YL5FZ2Y5U1 (Methotrexate)
-
Entry Date(s):
-
Date Created: 20201114 Date Completed: 20210818 Latest Revision: 20211204
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.blre.2020.100772
-
PMID:
-
33187812
-
Treatment options for newly diagnosed aplastic anemia (AA) patient includes upfront allogeneic hematopoietic stem cell transplant (HSCT) or immunosuppressive therapy (IST). With recent advances in supportive care, conditioning regimens and post-transplant immunosuppression the overall survival for HSCT approaches 70-90%. Transplant eligibility needs to be assessed considering age, comorbidities, donor availability and probability of response to immunosuppressive therapy (IST). Upfront HSCT should be offered to children and young adults with matched related donor (MRD). Upfront HSCT may also be offered to children and young adults with rapidly available matched unrelated donor (MUD) who require urgent HSCT. Bone marrow (BM) graft source and cyclosporine (CsA) plus methotrexate (MTX) as graft versus host disease (GVHD) prophylaxis are preferable when using anti-thymocyte globulin (ATG) based conditioning regimens. Alemtuzumab is an acceptable alternative to ATG and is used with CsA alone and with either BM or peripheral blood stem cells (PBSC). Cyclophosphamide (CY) plus ATG conditioning is preferable for patients receiving MRD transplant, while Fludarabine (Flu) based conditioning is reserved for older adults, those with risk factors of graft failure and those receiving MUD HSCT. For haploidentical transplant, use of low dose radiotherapy and post-transplant cyclophosphamide has resulted in a marked reduction in graft failure and GVHD.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
